Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie He(First Affiliated Hospital of Jinan University), Ziran Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yousheng Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Ling(Zhejiang Chinese Medical University), Kang Shao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yibo Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Nan Sun(Ministry of Education), Ning Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yue Yu(Xijing Hospital), Fan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhijie Wang(Hubei University of Medicine), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dawei Wu(Chinese PLA General Hospital), Lei Zhang(Institute of Hematology & Blood Diseases Hospital), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Dali Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Tang, Shun He(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Wu(Regeneron (United States)), Kai Su(Sun Yat-sen University), Jun Zhao(Chinese Academy of Sciences), Liang Zhao(Linyi City Chinese Medicine Hospital), Shuhang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiuli Tao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wendong Lei(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Shun‐Yu Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Lv(Liaoning Normal University)
Cited by 415
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k